Protalex Inc. Continues Progress on Its BioRegulator Technology

Dec 12, 2000, 00:00 ET from Protalex Inc.

    ALBUQUERQUE, N.M., Dec. 12 /PRNewswire/ -- Protalex Inc.
 (OTC Bulletin Board:   PRTX), a biopharmaceutical firm announces the completion
 of an approximate $500,000 private placement of its common stock.  The Company
 also continues to make substantial progress in its efforts to develop its
 unique approach to the management of arthritis.  Almost all therapeutic
 approaches focus on the end product manifestations of the disease process
 which, by their very nature, can only alleviate symptoms.  Protalex's
 BioRegulators modulate the disease process itself.  This approach allows the
 biological system to re-establish its inherent control mechanisms in the
 complete absence of the toxic side-effects so often associated with
 palliation.  The Company's approach involves the integration of three stages
 of laboratory investigation along with the immediate development of clinical
 application.  The stages are:
     -- The first is an in vitro cell culture system, which allows the
        screening of large numbers of compounds for BioRegulator activity.
        BioRegulators must initiate or modulate cellular differentiation of
        normal cells and re-regulate the same mechanisms in abnormal cells in
        both animal and human models in order to qualify for further studies.
     -- The second system is in vivo animal models where the BioRegulator must
        demonstrate similar process modifying activity at dosage levels,
        defined by the cell culture models, which are below any known toxic
     -- The third system is also an in vivo model.  These animals have either
        genetic, or chemically induced arthritis-like, disease.  Again, the
        BioRegulator must affect the animals' entire physiology in an
        integrated fashion.  The dosage levels must be similar to those defined
        by both the in vitro cell culture system and the in vivo animal models.
     The Company can now announce the successful completion of the
 identification of a family of BioRegulators which meet all the Company's
 criteria.  This family of compounds ranges from a natural product to its
 active, small molecular weight, subcomponents.
     Statements in this press release that are not strictly historical are
 "forward-looking" statements within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
 These statements involve a high degree of risk and uncertainty, are
 predictions only and actual events or results may differ materially from those
 projected in such forward-looking statements.  Factors that could cause or
 contribute to differences include the Company's limited operating history,
 uncertainty regarding viability and market acceptance of the Company's
 products, and the Company's dependence on reimbursement by third parties.
 These factors and others are more fully described in the section entitled
 "Risks Related to the Company's Business" in the Company's Registration
 Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and
 Exchanges Commission.

SOURCE Protalex Inc.